Collaboration - November 30, 2021
Immunicum and PCI Biotech extend their collaboration
Immunicum and PCI Biotech Holding have announced an extension of their current research collaboration to explore novel cancer vaccination treatments. The companies jointly research the possibility to overcome current hurdles in cancer immunotherapy by introducing tumor independent immune targets into the tumor microenvironment, in combination with vaccination or adoptive immunotherapies. The so-called Tumor Independent Antigen […]
Intellectual Property - February 5, 2020
PCI Biotech granted US patent
PCI Biotech has announced that the U.S. Patent and Trademark Office (USPTO) has granted the company a US patent covering the use of fimaVacc in combination with cytokines. Cytokines are small proteins that are involved in cell signaling, and that are very important in the immune system, modulating both cell-based and humoral immune responses. The […]
Biotech Business - November 13, 2016
PCI Biotech with share issue in November
PCI Biotech has initiated a process with the objective to carry out a share issue in the range of NOK 40-50 million by the end of November 2016. Two of the largest shareholders have pledged that they will at least follow up their pro-rata in the share issue. Fondsfinans is retained as advisors in this […]
Drug development - August 12, 2016
PCI Biotech receives positive opinion from EMA
PCI Biotech has announced that it has received a positive opinion from the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) for its lead product candidate, fimaporfin, for the treatment of cholangiocarcinoma (bile duct cancer). COMP’s positive opinion is subject to decision by the European Commission for Orphan Designation. Fimaporfin (AmphinexTM) is in clinical […]
Biotech Business - January 29, 2016
PCI Biotech and Ultimovacs collaborates
PCI Biotech and Ultimovacs are initiating a preclinical research collaboration. The purpose of the collaboration is to utilise the companies’ complementary scientific platforms to explore potential synergies. Both companies are situated in the Oslo Cancer Cluster Incubator. The partnership is governed by a preclinical research collaboration agreement. In brief, the preclinical research collaboration will evaluate technology […]
Collaboration - April 20, 2015
PCI Partners With U.S. Firm
Norway’s PCI Biotech is initiating a pre-clinical research collaboration with American biotechnology company RXi Pharmaceuticals. The purpose of the pre-clinical research collaboration “is to utilize the companies’ complementary scientific platforms to explore potential synergies,” according to information from PCI Biotech. The partnership will evaluate technology compatibility based on in vitro and in vivo studies. Each […]
